Liquidia Corp is a biopharmaceutical firm based in Morrisville, North Carolina, focusing on creating innovative treatments for patients with unmet medical needs. Its flagship product, YUTREPIA, is an inhaled dry powder version of treprostinil designed to address pulmonary arterial hypertension. Additionally, the company offers a generic treprostinil injection, expanding its impact on patient care. Founded in 2004, Liquidia continues to pioneer in the healthcare sector, aiming to improve quality of life through advanced medical solutions.
Friday's top analyst upgrades and downgrades included Barrick Gold, DraftKings, Hyatt Hotels, Nikola, Occidental Petroleum, Penn National Gaming, Shopify, T-Mobile, Uber, Valero Energy and Workday.
A new research report outlines favorable Liquidia Technologies drug study data that will be presented in the coming weeks, which could add up to more than 300% potential upside.
Jon C. Ogg 